We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lab-On-Chip Platform to Expedite Cancer Diagnoses

By LabMedica International staff writers
Posted on 30 Jan 2025

Cancer was responsible for nearly 10 million deaths in 2020, accounting for almost one in every six deaths worldwide. More...

Timely cancer diagnosis remains a major challenge, as abnormal cellular growth is often detected too late. Early diagnosis is critical, and recent research has focused on detecting rare circulating tumor cells (CTCs) in peripheral blood as noninvasive markers for diagnosis. However, isolating target cells for examination is inherently difficult. Traditional methods typically require complex sample preparation, substantial equipment, and large sample volumes, and even then, it remains challenging to efficiently separate the cells.

Researchers from K. N. Toosi University of Technology (Tehran, Iran) have now introduced a groundbreaking system that uses standing surface acoustic waves to separate CTCs from red blood cells with remarkable precision and efficiency. The system developed by the team integrates advanced computational modeling, experimental analysis, and artificial intelligence (AI) algorithms to analyze complex acoustofluidic phenomena. By combining machine learning algorithms with data-driven modeling, they were able to fine-tune the system for optimal recovery and cell separation rates. The platform, described in the journal Physics of Fluids, achieves 100% recovery under ideal conditions, while significantly reducing energy consumption through precise control of acoustic pressures and flow rates.

While many methods for enriching particles through microfluidics have been developed, those using acoustofluidics stand out due to their biocompatibility, ability to generate high-force magnitudes at MPa pressure ranges, and production of cell-scale wavelengths. The researchers' novel approach incorporates dualized pressure acoustic fields, which enhance the impact on target cells, and positions them strategically at critical points in the microchannel geometry on a lithium niobate substrate. By applying acoustic pressure within the microchannel, the system generates reliable datasets that reveal cell interaction times and trajectory patterns, helping to predict tumor cell migration.

“We have produced an advanced, lab-on-chip platform that enables real-time, energy-efficient, and highly accurate cell separation,” said researcher Afshin Kouhkord. “The technology promises to improve CTC separation efficiency and open new possibilities for earlier and more effective cancer diagnosis. It also paves the way for microengineering and applied AI in personalized medicine and cancer diagnostics.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.